M.V. Ezhov

SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI “Russian Cardiological Research and Production Complex” of RMH, Moscow
Cardiovascular diseases of atherosclerotic origin make a significant contribution to morbidity and mortality in the Russian Federation. Hypercholesterolemia is the leading risk factor for the development of coronary artery disease. The metabolism of low-density lipoproteins (LDL) depends on the activity of the enzyme – proprotein convertase subtilisin/kexin type 9 (PCSK9). A new class of drugs – monoclonal antibodies – inhibits PCSK9 and leads to a marked decrease in LDL cholesterol. An extensive evidence base characterizes ehvolocumab as a safe and effective hypolipidemic agent, which helps to reduce the high risk of developing cardiovascular complications. The use of evolocoumab in patients with clinically significant atherosclerosis and lack of achievement of the target LDL cholesterol levels despite the maximum tolerated therapy with statins with or without ezetimibe, with familial heterozygous and homozygous hypercholesterolemia, and with statin intolerance is justified.

About the Autors

Corresponding author: M.V. Ezhov – MD, Leading Researcher at the Department of Atherosclerosis Problems SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI RSRPC of RMH, Moscow; e-mail: Marat_Ezhov@mail.ru

Similar Articles

Бионика Медиа